

## 8 Literaturverzeichnis

1. Aiken AH, Stone JA. Alveolar soft-part sarcoma of the tongue. *Am J Neuroradiol* 2003;24(6):1156-1158.
2. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. *The Lancet* 2004;363:1665-1672.
3. Antman KH., Ryan L., Elias A., Sherman D., Grier HE. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. *J Clin Oncol* 1989;7:126-131.
4. Aronson S, Garcia J, Aronson B. Metastatic neoplasms of the brain: their frequency in relation to age. *Cancer* 1964;7:558-563.
5. Asvall JE, Hoeg K, Kleppe K, Prydz PE. Alveolar soft part sarcoma. *Clin Radiol* 1969;20(4):426-432.
6. Auchter RM, Lamond JP, Alexander E, et al. A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. *Int J Radiat Oncol Biol Phys* 1996;35:27-35.
7. Auerbach HE, Brooks JJ. Alveolar soft part sarcoma. A clinicopathologic and immunohistochemical study. *Cancer* 1987;60(1):66-73.
8. Balfour RS. The alveolar soft-part sarcoma: review of the literature and report of case. *J Oral Surg* 1974;32(3):214-220. Review.
9. Baram TZ, van Tassel P, Jaffe NA. Brain metastases in osteosarcoma: Incidence, clinical and neurological findings and management options. *J Neurooncol* 1988;6:47-52.
10. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. *J Clin Oncol* 2004;14(22):2865-2872.
11. Batsakis JG. Alveolar soft-part sarcoma. *Ann Otol Rhinol Laryngol* 1988;97(3 Pt 1):328-329.
12. Baum ES, Fickenscher L, Nachman JB, Idriss F. Pulmonary resection and chemotherapy for metastatic alveolar soft-part sarcoma. *Cancer* 1981;47(8):1946-1948.
13. Beltran J, Simon DC, Katz W, Weis LD. Increased MR signal intensity in skeletal muscle adjacent to malignant tumors: pathological correlation and Clinical Relevance. *Radiology* 1997;162:251-255.
14. Berenzweig MS, Muggia FM, Kaplan BH. Chemotherapy of alveolar soft part sarcoma: a case report. *Cancer Treat Rep* 1977;61(1):77-79.

15. Bindal AK, Bindal RK, Hess KR, et al. Surgery versus radiosurgery in the treatment of brain metastasis. *J Neurosurg* 1996;84:748-754.
16. Bindal RK, Sawaya RE, Leavens ME, Lee JJ. Surgical treatment of multiple brain metastases. *J Neurosurg* 1993;79:210-216.
17. Bindal RK, Sawaya RE, Leavens ME, Taylor SH, Guinee VF. Sarcoma metastatic to the brain: results of surgical treatment. *Neurosurgery* 1994;35(2):185-190; discussion 190-191.
18. Blay JY, van Glabbeke M, Verweij J, et al. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. *Eur J Cancer* 2003;39(1):64-69.
19. Blumberg MB, Chang CH. Alveolar soft part sarcoma. *South Med J* 1976;69(3):282-285.
20. Bots GT, Tijssen CC, Wijnalda D, Teepen JL. Alveolar soft part sarcoma of the pituitary gland with secondary involvement of the right cerebral ventricle. *Br J Neurosurg* 1988;2(1):101-107.
21. Bouffet E, Doumi N, Thiesse P, et al. Brain metastases in children with solid tumors. *Cancer* 1997;79:403-410.
22. Bramwell VHC, Mouridsen HAT, Santoro A, et al. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. *Eur J Cancer Clin Oncol* 1987;23:311-321.
23. Broadbent AM, Hruby G, Tin MM, Jackson M, Firth I. Survival following whole brain radiation treatment for cerebral metastases: an audit of 474 patients. *Radiother Oncol* 2004;71:259-265.
24. Bryant BM, Wiltshaw E. Central nervous system involvement in sarcoma. *Eur J Cancer* 1980;16:1503-1507.
25. Cairncross JG, Kim JH, Posner JB. Radiation therapy for brain metastases. *Ann Neurol* 1980;7:529-541.
26. Casanova M, Ferrari A, Bisogno G, et al. Carli M. Alveolar soft part sarcoma in children and adolescents: A report from the Soft-Tissue Sarcoma Italian Cooperative Group. *Ann Oncol* 2000;11(11):1445-1449. Review.
27. Casper ES, Waltzman RJ, Schwartz GK, Natale RB. A phase II trial of paclitaxel in patients with soft tissue sarcomas. *Cancer Invest* 1998;16:442-446.
28. Charrier JB, Esnault O, Brette MD, Monteil JP. Alveolar soft-part sarcoma of the cheek. *Br J Oral Maxillofac Surg* 2001;39(5):394-397.
29. Chevallier B, Leyraz S, Olivier JP, Fargeot P, Facchini T, Vo-Van ML. Epirubicin and ifosfamide in advanced soft tissue sarcoma: a phase II study. *Cancer Invest* 1993;11:135-139.

30. Christopherson WM, Foote FW Jr, Stewart FW. Alveolar soft-part sarcoma: structurally characteristic tumors of uncertain histogenesis. *Cancer* 1952;5:100-111.
31. Crin JR, Seeger LL, Yao L, Chandani V, Eckardt JJ. Diagnosis of Soft-Tissue masses with MR Imaging: can benign masses be differentiated from malignant ones? *Radiology* 1992;185:581-586.
32. Daly BD, Cheung H, Gaines PA, Bradley MJ, Metreweli C. Imaging of alveolar soft part sarcoma. *Clin Radiol* 1992;46(4):253-256.
33. Datta R, Jawahar A, Ampil FL, Shi R, Nanda A, D'Agostino H. Survival in relation to radiotherapeutic modality for brain metastasis. *Am J Clin Oncol* 2004;27(4):420-424.
34. Davos I, Abell MR. Sarcomas of the vagina. *Obstet Gynecol* 1976;47:342-350.
35. Dei Tos AP, Dal Cin P. The role of cytogenetics in the classification of soft tissue tumours. *Virchows Arch* 1997;431:83-94.
36. Dietel M, Dudenhausen JW, Suttorp N. *Harrisons Innere Medizin 2 Bde.* ABW-Verlag. 15. Auflage,2002.
37. Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue sarcomas. The cumulative multicenter European experience. *Ann Surg* 1996;224:756-764.
38. Elias AD, Ryan L, Sulkes A, Collins J, Aisner J, Antman KH. Response to mesna, doxorubicin ifosfamide in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. *J Clin Oncol* 1989;7:1208-1216.
39. Enzinger FM, Weiss SW. Alveolar soft part sarcoma. *Soft Tissue Tumors*, 3<sup>rd</sup> ed. St. Louis: CV Mosby. 1995;13:1067-1074.
40. Espana P, Chang P, Wiernik P. Increased incidence of brain metastases in sarcoma patients. *Cancer* 1980;45:377-380.
41. Espat NJ, Bilsky M, Lewis JJ, Leung D, Brennan MF. Soft tissue sarcoma brain metastases. Prevalence in a cohort of 3829 patients. *Cancer* 2002;94(10):2706-2711.
42. Evans HL. Alveolar soft-part sarcoma. A study of 13 typical examples and one with a histologically atypical component. *Cancer* 1985;55(4):912-917.
43. Fata F, O'Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. *Cancer* 1999;86:2034-2037.
44. Fieber SS, Sherry RW. Alveolar soft-part sarcoma. *J Med Soc N J.* 1974;71(6):447-450.
45. Fisher ER. Histochemical observations on an alveolar soft-part sarcoma with reference to histogenesis. *Amer J Pathol* 1956;32:721-737.

46. Fleckenstein K, Hof H, Lohr F, Wenz F, Wannemacher M. Prognostic factors for brain metastases after whole brain radiotherapy. *Strahlenther Onkol* 2004;180:268-273.
47. Flieder DB, Moran CA, Suster S. Primary alveolar soft-part sarcoma of the mediastinum: a clinicopathological and immunohistochemical study of two cases. *Histopathology* 1997;31(5):469-473.
48. Folkman J. Successful treatment of an angiogenic disease. *N Engl J Med* 1989;320:1211-1212.
49. Font RL, Jurco S 3rd, Zimmerman LE. Alveolar soft-part sarcoma of the orbit: a clinicopathologic analysis of seventeen cases and a review of the literature. *Hum Pathol* 1982;13(6):569-579.
50. Foschini MP, Eusebi V. Alveolar soft-part sarcoma: a new type of rhabdomyosarcoma? *Semin Diagn Pathol* 1994;11(1):58-68. Review.
51. Frustaci S, Foladore S, Buonadonna A, et al. Epirubicin and ifosfamide in advanced soft tissue sarcomas. *Ann Oncol* 1993;4:669-672.
52. Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: Results of the italian randomized cooperative trial. *J Clin Oncol* 2001;19:1238-1247.
53. Furey JG, Barrett DL, Seibert RH. Alveolar soft-part sarcoma. Report of a case presenting as a sacral bone tumor. *J Bone Joint Surg Am* 1969;51(1):185-190.
54. Gercovich FG, Luna MA, Gottlieb JA. Increased incidence of metastases in sarcoma with prolonged survival from chemotherapy. *Cancer* 1975;36:1843-1851.
55. Getman V, Devyatko E, Dunkler D, et al. Prognosis of patients with non-small cell lung cancer with isolated brain metastases undergoing combined surgical treatment. *Eur J Cardiothorac Surg* 2004;25:1107-1113.
56. Gordon MS, Hajdu SI, Bains MS, Burt ME. Soft tissue sarcomas of the chest wall. Results of surgical resection. *J Thorac Cardiovasc Surg* 1991;101(5):843-854.
57. Hanna NN, O'Donnell K, Wolfe GR. Alveolar soft part sarcoma metastatic to the breast. *J Surg Oncol* 1996;61(2):159-162.
58. Hays DM. Rhabdomyosarcoma. *Clin Orthop* 1993;289:36-49.
59. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of phase II trial. *J Clin Oncol* 2002;20:2824-2831.
60. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-Function Mutations of c-kit in Human Gastrointestinal Stromal Tumors. *Science* 1998;279:577-580.
61. Ho KL. Sarcoma metastatic to the central nervous system: report of three cases and review of the literature. *Neurosurgery* 1979 Jul;5(1 Pt 1):44-48.

62. Hunter BC, Devaney KO, Ferlito A, Rinaldo A. Alveolar soft part sarcoma of the head and neck region. *Ann Otol Rhinol Laryngol* 1998;107(9 Pt 1):810-814.
63. Hurt R, Bates M, Harrison W. Alveolar soft-part sarcoma. *Thorax* 1982;37(12):877-886.
64. Iwamoto Y, Morimoto N, Chuman H, Shinohara N, Sugioka Y. The role of MR imaging in the diagnosis of alveolar soft part sarcoma: a report of 10 cases. *Skeletal Radiol* 1995;24(4):267-270.
65. James K, Eisenhauer E, Terenziani M, Vena D, Mudal A, Therasse P. Measuring response in solid tumors: undimensional versus bidimensional measurement. *J Natl Cancer Inst* 1999;91:523-528.
66. Jawahar A, Ampil F, Wielbaecher C, Hartman GH, Zhang JH, Nanda A. Management strategies for patients with brain metastases: Has radiosurgery made a difference? *South Med J* 2004;97(3):254-258.
67. Jong R, Kandel R, Fornasier V, Bell R, Bedard Y. Alveolar soft part sarcoma: review of nine cases including two cases with unusual histology. *Histopathology* 1998;32(1):63-68. Review.
68. Joyama S, Ueda T, Shimizu K, et al. Chromosome rearrangement at 17q25 and xp11.2 in alveolar soft-part sarcoma: A case report and review of the literature. *Cancer* 1999;86(7):1246-1250. Review.
69. Kasai K, Yoshida Y, Okumura M. Alveolar soft part sarcoma in the vagina: clinical features and morphology. *Gynecol Oncol* 1980;9(2):227-236.
70. Klos KJ, O'Neill BP. Brain metastases. *The Neurologist* 2004;10(1):31-46.
71. Kodama K, Doi O, Higashiyama M, et al. Surgery for multiple lung metastases from alveolar soft-part sarcoma. *Surg Today* 1997;27(9):806-811.
72. Kramer ED, Lewis D, Raney B, Womer R, Packer RJ. Neurologic complications in children with soft tissue and osseous sarcoma. *Cancer* 1989;64:2600-2603.
73. Kuriyama K, Todo S, Morimoto A, Imashuku S. Alveolar soft part sarcoma with lung metastases. Response to interferon alpha-2a? *Med Pediatr Oncol* 2001;37:482-483.
74. Kurtz JE, Andres E, Rohr S, et al. Pancreatic metastasis of alveolar soft-part sarcoma: a case report and review of the literature. *Ann Oncol* 2001;12(6):865-867.
75. Ladanyi M, Lui MY, Antonescu CR, et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. *Oncogene* 2001;20:48-57.
76. Lewis AJ. Sarcoma metastatic to the brain. *Cancer* 1988;61(3):593-601. Review.

77. Lieberman PH, Brennan MF, Kimmel M, Erlandson RA, Garin-Chesa P, Flehinger BY. Alveolar soft-part sarcoma. A clinico-pathologic study of half a century. *Cancer* 1989;63(1):1-13.
78. Lieberman PH, Foote FW Jr, Stewart FW, Berg JW. Alveolar soft-part sarcoma. *JAMA* 1966;198(10):1047-1051.
79. Lillehei KO, Kleinschmidt-DeMasters B, Mitchell DH, Spector E, Kruse CA. Alveolar soft part sarcoma: an unusually long interval between presentation and brain metastasis. *Hum Pathol* 1993;24(9):1030-1034.
80. Lock M, Chow E, Pond GR, et al. Prognostic factors in brain metastases: Can we determine patients who do not benefit from whole-brain radiotherapy? *Clin Oncol* 2004;16:332-338.
81. Loehrer PJ Sr, Sledge GW Jr, Nicaise C, et al. Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase III trial. *J Clin Oncol* 1989;7:1655-1659.
82. Lohr F, Pirzkall A, Hof H, Fleckenstein K, Debus J. Adjuvant treatment of brain metastases. *Semin Surg Oncol* 2001;20:50-56.
83. Lokich JJ. The management of cerebral metastasis. *JAMA* 1979;234:748-751.
84. Lorenzoni J, Devriendt D, Massager N, et al. Radiosurgery for treatment of brain metastases: Estimation of patient eligibility using three stratification systems. *Int J Radiat Oncol Biol Phys* 2004;60(1):218-224.
85. Lutterbach J, Bartelt S, Ostertag C. Long-term survival in patients with brain metastases. *J Cancer Res Clin Oncol* 2002;128:417-425.
86. MANUAL Knochentumoren und Weichteilsarkome. Tumorzentrum München und W. Zuckerschwerdt Verlag München. 4. Auflage, 2004.
87. Master K, Berkmen YM. Pulmonary metastases 15 years after removal of an alveolar soft-part sarcoma of the tongue. *Rev Interam Radiol* 1979 Jan;4(1):43-45.
88. Matsuno Y, Mukai K, Itabashi M, et al. Alveolar soft part sarcoma. A clinicopathologic and immunohistochemical study of 12 cases. *Acta Pathol Jpn* 1990;40(3):199-205.
89. Meredith JM, Kay S, Boshier LH. Case of granular-cell myoblastoma involving arm, lung and brain, with twenty years' survival. *J Thoracic Surg* 1958;35(1):80-90.
90. Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. *Cancer* 1996;78:1470-1476.
91. Mouridsen HT, Bastholt L, Somers R, et al. Adriamycin versus Epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III-study of the EORTC Soft tissue and Bone Sarcoma group. *Eur J Cancer Clin Oncol* 1987;23:1477-1483.

92. Mukai M, Iri H, Nakajima T, et al. Alveolar soft-part sarcoma. A review on its histogenesis and further studies based on electron microscopy, immunohistochemistry, and biochemistry. *Am J Surg Pathol* 1983;7(7):679-689.
93. Nakanishi K, Araki N, Yoshikawa H, Hashimoto T, Nakamura H. Alveolar soft part sarcoma. *Eur Radiol* 1998;8(5):813-816.
94. Nakashima Y, Kotoura Y, Kasakura K, Yamamuro T, Amitani R, Ohdera K. Alveolar soft-part sarcoma. A report of ten cases. *Clin Orthop* 1993;(294):259-266.
95. Nickerson HJ, Silberman T, Jacobsen FS, Krawisz BR, Maki HS, Arndt CA. Alveolar soft-part sarcoma responsive to intensive chemotherapy. *J Pediatr Hematol Oncol* 2004;26(4):233-235.
96. Nielsen GP, Oliva E, Young RH, Rosenberg AE, Dickersin GR, Scully RE. Alveolar soft-part sarcoma of the female genital tract: a report of nine cases and review of the literature. *Int J Gynecol Pathol* 1995;14(4):283-292. Review.
97. Nielsen OS, Dombernowsky P, Mouridsen H, et al. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. *Br J Cancer* 1998;78:1634-1639.
98. Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. *Int J Radiat Oncol Biol Phys* 1994;29:711-717.
99. Ogose A, Morita T, Hotta T, et al. Brain metastases in musculoskeletal sarcomas. *Jpn J Clin Oncol* 1999;29(5):245-247.
100. Ogose A, Yazawa Y, Ueda T, et al. Japanese Musculoskeletal Oncology Group. Alveolar soft part sarcoma in Japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group. *Oncology* 2003;65(1):7-13.
101. Ordonez NG. Alveolar soft part sarcoma: a review and update. *Adv Anat Pathol* 1999;6(3):125-139. Review.
102. Palumbo R., Palmeri S., Antimi M., et al. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. *Ann Oncol* 1997;8:1159-1162.
103. Pang LM, Roebuck DJ, Griffith JF, Kumta SM, Metreweli C. Alveolar soft-part sarcoma: a rare soft-tissue malignancy with distinctive clinical and radiological features. *Pediatr Radiol* 2001;31(3):196-199.
104. Pappo AS, Parham DM, Cain A, et al. Alveolar soft part sarcoma in children and adolescents: clinical features and outcome of 11 patients. *Med Pediatr Oncol* 1996;26(2):81-84.

105. Parasuraman S, Langston J, Rao B, et al. Brain metastases in pediatric Ewing sarcoma and rhabdomyosarcoma: The ST. Jude Children's Research Hospital experience. *J Pediatr Hematol Oncol* 1999;21:370-377.
106. Park YK, Unni KK, Kim YW, et al. Primary alveolar soft part sarcoma of bone. *Histopathology* 1999;35(5):411-417.
107. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. *N Engl J Med* 1990;322:494-500.
108. Patel SR, Vadhan-Raj S, Burgess MA, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. *Am J Clin Oncol*. 1998;21(3):317-321.
109. Perel Y, Rivel J, Alos N, Pignol ML, Guillard JM. Alveolar soft part sarcoma. A rare tumor of unusual evolution in pediatrics. *Am J Pediatr Hematol Oncol* 1993;15(4):435-438.
110. Perry JR, Bilbao JM. Metastatic alveolar soft part sarcoma presenting as a dural-based cerebral mass. *Neurosurgery* 1994;34(1):168-170.
111. Pollard SG, Marks PV, Temple LN, Thompson HH. Breast sarcoma. A clinicopathologic review of 25 cases. *Cancer* 1990;66(5):941-944.
112. Portera CA Jr, Ho V, Patel SR, et al. Alveolar soft part sarcoma: Clinical course and patterns of metastasis in 70 patients treated at a single institution. *Cancer* 2001;91 (3):585-591.
113. Postovsky S, Ash S, Ramu IN, et al. Central nervous system involvement in children with sarcoma. *Oncology* 2003;65(2):118-124.
114. Pratt CB, Pappo AS, Gieser P, et al. Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: A pediatric oncology group study. *J Clin Oncol* 1999;17(4):1219-1226.
115. Rades D, Raabe A, Bajrovic A, Alberti W. Treatment of solitary brain metastasis. *Strahlenther Onkol* 2004;3:144-147.
116. Radig K, Buhtz P, Roessner A. Alveolar soft part sarcoma of the uterine corpus. Report of two cases and review of the literature. *Pathol Res Pract* 1998;194(1):59-63. Review.
117. Reichardt P, Pink D, Hohenberger P. Paradigmenwechsel in der Therapie gastrointestinaler Stromatumoren. *Der Onkologe* 2002;8:378-383.
118. Reichardt P, Tilgner J, Hohenberger P, Dörken B. Dose-intensive chemotherapy with ifosfamide, epirubicin and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. *J Clin Oncol* 1998;16:1438-1443.
119. Reichardt P. High-dose chemotherapy in adult soft tissue sarcoma. *Crit Rev Oncol Hematol* 2002;41:157-167.



120. Roozendaal KJ, De Valk B, ten Velden JJ, van der Woude HJ, Kroon BB. Alveolar soft-part sarcoma responding to interferon alpha-2b. *Br J Cancer* 2003;89(2):243-235.
121. Rosenbaum AE, Gabrielsen TO, Harris H, Goldberg S. Cerebral manifestations of alveolar soft-part sarcoma. *Radiology* 1971;99(1):109-115.
122. Rosolen A, Todesco A, Colamonici OR, Basso G, Frascella E. Expression of type I interferon in solid tumors of childhood. *Mod Pathol* 1997;10:55-61.
123. Rubinfeld S. Radiation therapy in alveolar soft part sarcoma. *Cancer* 1971;28(3):577-580.
124. Saito T, Oda Y, Kawaguchi KI, et al. Possible association between tumor-suppressor gene mutations and hMSH2/hMLH1 Inactivation in alveolar soft part sarcoma. *Hum Pathol* 2003;34:841-849.
125. Salvati M, Cervoni L, Caruso R, Gagliardi FM, Delfini R. Sarcoma metastatic to the brain: a series of 15 cases. *Surg Neurol* 1998;49(4):441-444.
126. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. *J Clin Oncol* 1995;13(7):1537-1545.
127. Sarcoma Meta-analysis Collaboration: Adjuvant chemotherapy for localised respectable soft tissue sarcoma in adults. *Cochrane Database Syst Rev* 2000;4.
128. Sarno JB, Wiener L, Waxman M, Kwee J. Sarcoma metastatic to the central nervous system parenchyma: a review of the literature. *Med Ped Oncol* 1985;13:280-292.
129. Schmoll HJ, Höffken K, Possinger K. *Kompendium Internistische Onkologie* 3 Bde. Springer Berlin, 4. Auflage, 2006.
130. Schouten LJ, Rutten J, Huvneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon kidney, and lung and melanoma. *Cancer* 2002;94(10):2698-2705.
131. Schütte J, Mouridsen HAT, Stewart W, et al. EORTC Soft Tissue and Bone Sarcoma Group. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. *Eur J Cancer* 1990;26(5):558-561.
132. Shehata MK, Young B, Reid B, et al. Stereotactic radiosurgery of 468 brain metastases  $\leq 2$ cm: Implications for SRS dose and whole brain radiation therapy. *Int J Radiat Oncol Biol Phys* 2004;59(1):87-93.
133. Shen JT, D'ablaing G, Morrow CP. Alveolar soft part sarcoma of the vulva: report of first case and review of literature. *Gynecol Oncol.* 1982;13(1):120-128.
134. Sherman N, Vavilala M, Pollock R, Romsdahl M, Jaffe N. Radiation therapy for alveolar soft-part sarcoma. *Med Pediatr Oncol* 1994;22(6):380-383.

135. Simmons WB, Haggerty HS, Ngan B, Anonsen CK. Alveolar soft part sarcoma of the head and neck. A disease of children and young adults. *Int J Pediatr Otorhinolaryngol* 1989;17(2):139-153.
136. Skubitz KM, Hamdan H, Thompson RC. Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas. *Cancer* 1993;72(10):2963-2969.
137. Sneed PK, Suh JH, Goetsch SJ, et al. A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. *Int J Radiat Oncol Biol Phys* 2002;53:519-526.
138. Spector RA, Travis LW, Smith J. Alveolar soft part sarcoma of the head and neck. *Laryngoscope*. 1979;89(8):1301-1306.
139. Springfield D. Liposarcoma. *Clin Orthop* 1993;289:50-57.
140. Steward WP, Verweij J, Somers R, et al. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. *J Clin Oncol* 1993;11:15-21.
141. Sundaresan N, Galicich JH. Surgical treatment of brain metastases: Clinical and computerized tomography evaluation of the results of treatment. *Cancer* 1985;55:1382-1388.
142. Szklarski W, Wasilewska A, Gruchala A, et al. Alveolar soft part sarcoma: an analysis of 8 cases. Review of the literature. *Patol Pol* 1991;42(1):33-38. Review.
143. Takakura K, Sano K, Hojo S, Hirano A. *Metastatic Tumors of the Central Nervous System*. Tokyo: Igaku-Shoin, 1982.
144. Temple HT, Scully SP, O'Keefe RJ, Rosenthal DI, Mankin HJ. Clinical presentation of alveolar soft-part sarcoma. *Clin Orthop* 1994;300:213-218.
145. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. *J Nat Cancer Inst* 2000;92:205-216.
146. Tornoczky T, Kalman E, Sapi Z, Orosz Z, Pajor L. Cytogenetic abnormalities of alveolar soft-part sarcomas using interphase fluorescent in situ hybridization: trisomy for chromosome 7 and monosomy for chromosomes 8 and 18 seem to be characteristic of the tumor. *Virchows Arch* 2001;438(2):173-180.
147. Tursz T. High-dose ifosfamide in the treatment of advanced soft tissue sarcomas. *Semin Oncol* 1996;23: 34-39.
148. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. *J Clin Oncol* 1999;17(1):150-157.

149. van Oosterom AT, Mouridsen HT, Nielsen OS, et al. EORTC Soft Tissue and Bone Sarcoma Group. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. *Eur J Cancer* 2002;38(18):2397-2406.
150. van Ruth S, van Coevorden F, Peterse JL, Kroon BBR. Alveolar soft part sarcoma: a report of 15 cases. *Eur J Cancer* 2002;38:1324-1328.
151. Vanucci RC, Baten M. Cerebral metastatic disease in childhood. *Neurology* 1974;24:981-985.
152. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgery? *Ann Neurol* 1993;33:583-590.
153. Verweij J, Mouridsen HT, Nielsen OS, et al. The present state of the art in chemotherapy for soft tissue sarcomas in adults: EORTC point of view. *Crit Rev Oncol Hematol* 1995;20:193-201.
154. Wang CH, Lee N, Lee LS. Successful treatment for solitary brain metastasis from alveolar soft part sarcoma. *J Neurooncol* 1995;25(2):161-166. Review.
155. Weber U, Havemann K. [Treatment of alveolar soft part sarcoma]. *Arch Orthop Unfallchir* 1977;89(2):219-225.
156. Weh HJ, Zugel M, Wingberg D, et al. Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide. *Onkologie* 1990;13:448-452.
157. WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): World Health Organization Offset Publication No. 48;1979.
158. Wobbes T. Alveolar soft part sarcoma. *J Surg Oncol* 1978;10(3):201-204.
159. Wronski M, Arbit E, Burt M, Perino G, Galicich JH, Brennan MF. Resection of brain metastases from sarcoma. *Ann Surg Oncol* 1995;2:392-399.
160. Yoshida S, Morii K, Watanabe M, Saito T. Brain metastasis in patients with sarcoma: an analysis of histological subtypes, clinical characteristics and outcomes. *Surg Neurol* 2000;54:160-164.
161. Zaleski S, Setum C, Benda J. Cytologic presentation of alveolar soft-part sarcoma of the vagina. A case report. *Acta Cytol* 1986;30(6):665-670.